ACE2-IgM-Fc FUSION PROTEINS AND USES THEREOF

Organization Name

Regeneron Pharmaceuticals, Inc.

Inventor(s)

Nianshuang Wang of Cos Cob CT (US)

Yang Shen of Scarsdale NY (US)

Alina Baum of Pleasantville NY (US)

Christos Kyratsous of Irvington NY (US)

Chia-Yang Lin of Scarsdale NY (US)

ACE2-IgM-Fc FUSION PROTEINS AND USES THEREOF - A simplified explanation of the abstract

This abstract first appeared for US patent application 18588774 titled 'ACE2-IgM-Fc FUSION PROTEINS AND USES THEREOF

The present disclosure introduces ACE2 fusion proteins that bind to RBD regions of SARS-COV and/or SARS-COV-2, potentially treating conditions associated with these infections, such as COVID-19.

ACE2 fusion proteins consist of multimerization moieties linked to ACE2 moieties.
These fusion proteins specifically target the RBD regions of SARS-COV and SARS-COV-2.
Methods for producing ACE2 fusion proteins are included in the disclosure.
Pharmaceutical compositions containing ACE2 fusion proteins are part of the innovation.
The use of ACE2 fusion proteins to treat SARS-COV and SARS-COV-2 infections, like COVID-19, is detailed.

Potential Applications

The ACE2 fusion proteins could be used in the development of treatments for SARS-COV and SARS-COV-2 infections, including COVID-19.

Problems Solved

This technology addresses the need for targeted therapies for SARS-COV and SARS-COV-2 infections, potentially offering more effective treatment options.

Benefits

The use of ACE2 fusion proteins may lead to improved outcomes for individuals suffering from SARS-COV and SARS-COV-2 infections, potentially reducing the severity and duration of the illnesses.

Commercial Applications

The commercial applications of this technology could include the development of novel pharmaceuticals for the treatment of COVID-19 and other related infections, potentially impacting the healthcare industry significantly.

Questions about ACE2 Fusion Proteins

How do ACE2 fusion proteins differ from traditional treatments for SARS-COV and SARS-COV-2 infections?

ACE2 fusion proteins offer a targeted approach to treating these infections by specifically binding to the RBD regions of the viruses, potentially enhancing efficacy and reducing side effects compared to traditional treatments.

What are the potential challenges in the production and distribution of pharmaceutical compositions containing ACE2 fusion proteins?

Challenges may include scalability of production, regulatory approvals, and ensuring widespread access to these innovative treatments.

Original Abstract Submitted

The present disclosure provides ACE2 fusion proteins, comprising multimerization moieties linked to ACE2 moieties, that specifically bind to RBD regions of SARS-COV and/or SARS-COV-2. The present disclosure further relates to the methods of producing the ACE2 fusion proteins, pharmaceutical compositions comprising of the ACE2 fusion proteins, and methods of use of the ACE2 fusion proteins to treat conditions associated with SARS-COV and SARS-COV-2 infections, such as COVID-19.